HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antipsychotic drugs and reproductive hormones: relationship to body weight regulation.

Abstract
Excessive body weight gain is an undesirable side effect of prolonged administration of antipsychotic drugs (AP), which affects health and interferes with treatment compliance. It has been suggested that hyperprolactinemia-induced endocrine and metabolic abnormalities, particularly in the gonadal steroids, might be involved in the development of this type of weight gain. To test this hypothesis, reproductive hormones, cortisol, dehydro-epiandrosterone-sulfate (DHEA-S), thyroid hormones, and body weight gain were assessed in 18 patients (9 men, 9 women) with mental disorders receiving AP who had been medication-free for at least 3 months before the study, and in 27 placebo-treated subjects (10 men, 17 women). In women, hormones were evaluated during several phases of the menstrual cycle. A significant weight gain was observed in men but not in women. Under AP administration, women displayed significantly lower serum levels of estradiol and progesterone, whereas in men the levels of free testosterone and DHEA-S were significantly lower than in controls. Hyperprolactinemia was observed in both sexes. The levels of follicle-stimulating hormone in women and luteinizing hormone in men were significantly elevated by treatment, thus suggesting that the functioning of the hypothalamus-pituitary gonads was preserved. In men, such an endocrine profile resembles that observed in subjects with primary obesity. Women under AP administration were found to be relatively hyperandrogenic because of decreased serum estradiol levels, whereas women with primary obesity are known to display actual increased levels of androgens. These endocrine abnormalities may contribute to the excessive weight gain observed after AP treatment, and these could be the target of novel pharmacological treatments.
AuthorsT Baptista, D Reyes, L Hernández
JournalPharmacology, biochemistry, and behavior (Pharmacol Biochem Behav) Vol. 62 Issue 3 Pg. 409-17 (Mar 1999) ISSN: 0091-3057 [Print] United States
PMID10080231 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Androgens
  • Antipsychotic Agents
  • Gonadal Steroid Hormones
  • Thyroid Hormones
  • Progesterone
  • Estradiol
  • Dehydroepiandrosterone Sulfate
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
Topics
  • Adult
  • Androgens (blood)
  • Antipsychotic Agents (pharmacology)
  • Body Mass Index
  • Body Weight (drug effects)
  • Dehydroepiandrosterone Sulfate (blood)
  • Estradiol (blood)
  • Female
  • Follicle Stimulating Hormone (blood)
  • Gonadal Steroid Hormones (blood)
  • Humans
  • Luteinizing Hormone (blood)
  • Male
  • Progesterone (blood)
  • Schizophrenia (drug therapy)
  • Thyroid Hormones (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: